Clinical Trial: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma: Clinical Trial
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for nasopharyngeal carcinoma.
Detailed Summary: By enrolling patients with nasopharyngeal carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography （DSA） for nasopharyngeal carcinoma.
Sponsor: Fuda Cancer Hospital, Guangzhou
Current Primary Outcome: Number of participants with Adverse events [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Percentage of lesions interventional therapy that show no sign of recurrence 12 months after [ Time Frame: 1 year ]
- Progress free disease (PFS) [ Time Frame: 1 year ]
- Overall survival (OS) [ Time Frame: 3 year ]
Original Secondary Outcome: Same as current
Information By: Fuda Cancer Hospital, Guangzhou
Dates:
Date Received: August 12, 2015
Date Started: May 2015
Date Completion:
Last Updated: July 17, 2016
Last Verified: October 2015
